| 6.21 Data as of Jun 18 | +0.13 / +2.14%Today’s Change | 4.62 Today|||52-Week Range 7.27 | -0.32% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Medical Specialties | MARKET CAP $170.6M |
Company Description
CryoLife, Inc. operates as a biological medical device company, which preserves and distributes human tissues for transplantation and develops, manufactures, and commercializes medical devices for cardiac and vascular applications. The company operates in two reportable segments: Preservation Services and Medical Devices. The Preservation Services segment distributes preserved human cardiac and vascular tissue to implanting institutions throughout the United States, Canada and Europe. The Medical Devices segment includes marketing and distribution of BioGlue, BioFoam, PerClot, HemoStase and other medical devices. CryoLife distributes human tissues such as the CryoValve SG pulmonary heart valve and the CryoPatch SG pulmonary cardiac patch tissue; both processed using its SynerGraft technology. The company was founded by Steven G. Anderson on January 19, 1984 and is headquartered in Kennesaw, GA.
Employees

Shareholders
| Other institutional | 30.86% |
| Mutual fund holders | 26.44% |
| Individual stakeholders | 20.61% |
Top Executives
| Steven G. Anderson | Chairman, President & Chief Executive Officer |
| David Ashley Lee, CPA | COO, CFO, Treasurer, EVP & Head-Media Relations |
| Scott B. Capps | Vice President-Clinical Research |
| David C. Gale, PhD | Vice President-Research & Development |
| Jeffrey W. Burris | Vice President & General Counsel |